Overview

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
Phase:
Phase 2
Details
Lead Sponsor:
BioCryst Pharmaceuticals
Treatments:
Allopurinol